Free Trial
NASDAQ:RCKT

Rocket Pharmaceuticals Q3 2025 Earnings Results & Report

Rocket Pharmaceuticals logo
$2.39 -0.09 (-3.63%)
Closing price 04:00 PM Eastern
Extended Trading
$2.37 -0.02 (-0.84%)
As of 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rocket Pharmaceuticals beat analyst earnings expectations in its Q3 2025 results, released November 6, 2025. The company reported EPS of -$0.45 versus the -$0.48 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Rocket Pharmaceuticals EPS Results

Actual EPS
-$0.45
Consensus EPS
-$0.48
Beat/Miss
Beat by +$0.03
One Year Ago EPS
-$0.71
EPS Beat Rate
6 of last 8 quarters

Rocket Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
$327 thousand
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Rocket Pharmaceuticals' Q4 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules

Rocket Pharmaceuticals Q3 2025 Earnings FAQ

Rocket Pharmaceuticals (NASDAQ:RCKT) reported earnings of -$0.45 per share for Q3 2025, beating the consensus estimate of -$0.48. The report was announced on Thursday, November 6, 2025.

Rocket Pharmaceuticals' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Rocket Pharmaceuticals on the company's earnings history page.

Rocket Pharmaceuticals Earnings Headlines

Rocket Pharmaceuticals Inc (RCKT)
Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
See More Rocket Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rocket Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rocket Pharmaceuticals and other key companies, straight to your email.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals (NASDAQ:RCKT) is a biotechnology company developing gene therapies for rare, serious diseases, with a focus on inherited disorders that often affect children. Its research programs use lentiviral and adeno-associated viral (AAV) vector technologies to deliver therapeutic genes to patients’ cells.

The company’s pipeline has included programs targeting conditions such as Fanconi anemia, leukocyte adhesion deficiency-I, pyruvate kinase deficiency, Danon disease and arrhythmogenic cardiomyopathy. Rocket conducts research and clinical development from its base in Cranbury, New Jersey, and works to advance its therapies through clinical testing and regulatory review.

View Rocket Pharmaceuticals Profile